Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HOVON HO182 CLL venetoclax duration trial after venetoclax + rituximab
NL-OMON61222Phase 3Recruiting
- Sponsor
- HOVON
- Start
- Sep 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of venetoclax and rituximab in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (2 arms), sponsored by HOVON. Primary endpoint: Progression-free survival. Started Sep 2026; status: recruiting.
02
Drugs
venetoclaxrituximab
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on NL-OMON61222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61222.